WINT

Windtree Therapeutics (WINT)

Windtree Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:WINT

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/16	05 : 59	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:WINT	Windtree Therapeutics Inc
2024/05/09	21 : 41	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:WINT	Windtree Therapeutics Inc
2024/05/07	21 : 00	GlobeNewswire Inc.	Windtree Therapeutics Regains Compliance with Nasdaq	NASDAQ:WINT	Windtree Therapeutics Inc
2024/04/18	21 : 00	GlobeNewswire Inc.	Windtree Therapeutics Announces Reverse Stock Split	NASDAQ:WINT	Windtree Therapeutics Inc
2024/04/17	21 : 00	GlobeNewswire Inc.	Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates	NASDAQ:WINT	Windtree Therapeutics Inc
2024/04/09	05 : 48	GlobeNewswire Inc.	Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing	NASDAQ:WINT	Windtree Therapeutics Inc
2024/02/17	07 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/02/15	07 : 23	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:WINT	Windtree Therapeutics Inc
2024/02/15	06 : 30	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:WINT	Windtree Therapeutics Inc
2024/02/14	10 : 15	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:WINT	Windtree Therapeutics Inc
2024/02/13	06 : 40	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:WINT	Windtree Therapeutics Inc
2024/02/02	07 : 26	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:WINT	Windtree Therapeutics Inc
2024/02/01	22 : 00	GlobeNewswire Inc.	Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/31	22 : 40	InvestorsHub NewsWire	Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/31	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/31	22 : 00	GlobeNewswire Inc.	Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/25	23 : 04	InvestorsHub NewsWire	Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/25	22 : 34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/25	22 : 30	GlobeNewswire Inc.	Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/23	06 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/17	22 : 00	GlobeNewswire Inc.	Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/17	21 : 56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/17	06 : 16	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:WINT	Windtree Therapeutics Inc
2024/01/03	06 : 05	GlobeNewswire Inc.	Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator	NASDAQ:WINT	Windtree Therapeutics Inc
2023/12/18	22 : 00	GlobeNewswire Inc.	Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock	NASDAQ:WINT	Windtree Therapeutics Inc
2023/11/16	22 : 00	GlobeNewswire Inc.	Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent	NASDAQ:WINT	Windtree Therapeutics Inc
2023/11/14	01 : 41	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:WINT	Windtree Therapeutics Inc
2023/11/10	06 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:WINT	Windtree Therapeutics Inc
2023/11/10	06 : 15	GlobeNewswire Inc.	Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates	NASDAQ:WINT	Windtree Therapeutics Inc
2023/11/10	06 : 11	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:WINT	Windtree Therapeutics Inc